§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇨🇦Canada	🇪🇺European Union
Authority & dossier
Regulatory authority	HC HPFB	EMA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA, EMA, MHRA, TGA +2	—
Lead pathway (timeline & fees) — New Drug Submission (NDS) · Centralised Procedure
Pathway name	New Drug Submission (NDS)	Centralised Procedure
Approval timeline	300–365 days	210–277 days
Application fee	CAD 539,663	EUR 358,800
Annual renewal	CAD 4,129	EUR 122,500
Local representative	Not required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	No	Yes
Local responsible person	Yes	Yes
RP role	Canadian Senior Officer responsible for the establishment licence, Quality Assurance Person (QA) for batch release, and Senior Medical Adviser for drug safety reporting. Canadian importer DEL holder takes physical receipt of imported products.	Qualified Person Responsible for Pharmacovigilance (QPPV) — must reside and operate in the EU/EEA — is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Priority Review, Notice of Compliance with Conditions (NOC/c), Advance Consideration under Notice of Compliance +1	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Three categories: Notifiable Changes (notification, certain low-risk changes), Supplemental NDS (S/NDS — prior approval, mid-tier and major changes), and Annual Notification (consolidates minor administrative updates). The Post-NOC Changes Quality Document and Post-NOC Changes Safety and Efficacy Document specify classification.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor — Do and Tell, 12-month notification), Type IAIN (minor — immediate notification), Type IB (minor — Tell, Wait, and Do, 30-day default), Type II (major — prior approval, 60–90 days), and Extensions (Annex I changes — full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	No periodic renewal of NDS — DIN remains valid indefinitely subject to compliance and payment of annual Right to Sell fee. Annual Drug Notification Form required to confirm marketing status.	Initial 5-year renewal — application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	Vanessa's Law (Protecting Canadians from Unsafe Drugs Act, 2014) significantly strengthened post-market authorities — including mandatory hospital ADR reporting (in force since 2019), authority to require label changes, and authority to require post-market studies. PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs) on harmonised birth dates. Canada Vigilance is the spontaneous reporting system; MedEffect Canada provides safety communications.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–30 days	60–106 days
GCP standard	ICH E6(R3) — Health Canada adopted via guidance update 2025; Division 5 FDR	ICH E6(R3) — Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	Yes
HTA required	Yes	Yes
HTA body	Canada's Drug Agency (formerly CADTH, rebrand 2024); INESSS for Quebec	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

CanadaHC HPFB
European UnionEMA

English submissions

CanadaYes
European UnionYes

CTD accepted

CanadaYes
European UnionYes

eCTD accepted

CanadaYes
European UnionYes

Reliance pathway

CanadaAvailable
European UnionAvailable

Reference agencies

CanadaFDA, EMA, MHRA, TGA +2
European Union—

Lead pathway (timeline & fees) — New Drug Submission (NDS) · Centralised Procedure

Pathway name

CanadaNew Drug Submission (NDS)
European UnionCentralised Procedure

Approval timeline

Canada300–365 days
European Union210–277 days

Application fee

CanadaCAD 539,663
European UnionEUR 358,800

Annual renewal

CanadaCAD 4,129
European UnionEUR 122,500

Local representative

CanadaNot required
European UnionRequired

Local manufacturing

CanadaNot required
European UnionNot required

GMP inspection

CanadaRequired
European UnionRequired

MAH & local presence

Local entity required

CanadaNo
European UnionYes

Local responsible person

CanadaYes
European UnionYes

RP role

CanadaCanadian Senior Officer responsible for the establishment licence, Quality Assurance Person (QA) for batch release, and Senior Medical Adviser for drug safety reporting. Canadian importer DEL holder takes physical receipt of imported products.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV) — must reside and operate in the EU/EEA — is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Canada4 designations
European Union6 designations

Examples

CanadaPriority Review, Notice of Compliance with Conditions (NOC/c), Advance Consideration under Notice of Compliance +1
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

CanadaThree categories: Notifiable Changes (notification, certain low-risk changes), Supplemental NDS (S/NDS — prior approval, mid-tier and major changes), and Annual Notification (consolidates minor administrative updates). The Post-NOC Changes Quality Document and Post-NOC Changes Safety and Efficacy Document specify classification.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor — Do and Tell, 12-month notification), Type IAIN (minor — immediate notification), Type IB (minor — Tell, Wait, and Do, 30-day default), Type II (major — prior approval, 60–90 days), and Extensions (Annex I changes — full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

CanadaNo periodic renewal of NDS — DIN remains valid indefinitely subject to compliance and payment of annual Right to Sell fee. Annual Drug Notification Form required to confirm marketing status.
European UnionInitial 5-year renewal — application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

CanadaVanessa's Law (Protecting Canadians from Unsafe Drugs Act, 2014) significantly strengthened post-market authorities — including mandatory hospital ADR reporting (in force since 2019), authority to require label changes, and authority to require post-market studies. PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs) on harmonised birth dates. Canada Vigilance is the spontaneous reporting system; MedEffect Canada provides safety communications.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

CanadaAvailable
European UnionAvailable

Compassionate Use

CanadaAvailable
European UnionAvailable

Emergency Import

CanadaAvailable
European UnionAvailable

Parallel Import

CanadaNot permitted
European UnionPermitted

Clinical trials

CTA approval

CanadaRequired
European UnionRequired

Ethics approval

CanadaYes
European UnionYes

CTA timeline

Canada30–30 days
European Union60–106 days

GCP standard

CanadaICH E6(R3) — Health Canada adopted via guidance update 2025; Division 5 FDR
European UnionICH E6(R3) — Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

CanadaRegulated
European UnionRegulated

Reference pricing

CanadaYes
European UnionYes

HTA required

CanadaYes
European UnionYes

HTA body

CanadaCanada's Drug Agency (formerly CADTH, rebrand 2024); INESSS for Quebec
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)